Table 3.

Summary of Treatment‐Emergent Adverse Events Within Each of the DDI Study Arms

	Gemfibrozil	Itraconazole	Rifampin
	DDI Arm	DDI Arm	DDI Arm
TEAE	(n = 20)	(n = 20)	(n = 20)
Any TEAE	9 (45)	2 (10)	7 (37)
Any severe TEAE	0	0	0
Any serious TEAE	0	0	0
AE leading to discontinuation	1 (5)	0	1 (5)
On‐study deaths	0	0	0

AE indicates adverse event; DDI, drug‐drug interaction; TEAE, treatment‐emergent adverse event.

Data are n (%).